Literature DB >> 20977692

Intravitreal bevacizumab for retinal macroaneurysm.

Jost B Jonas, Matthias Schmidbauer.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20977692     DOI: 10.1111/j.1755-3768.2009.01675.x

Source DB:  PubMed          Journal:  Acta Ophthalmol        ISSN: 1755-375X            Impact factor:   3.761


× No keyword cloud information.
  7 in total

1.  Intravitreal ranibizumab in retinal macroaneurysm.

Authors:  Andrea R Wenkstern; Heike Petersen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-05-28       Impact factor: 3.117

2.  Subretinal injection of recombinant tissue plasminogen activator for submacular hemorrhage associated with ruptured retinal arterial macroaneurysm.

Authors:  Makoto Inoue; Fumio Shiraga; Yukari Shirakata; Yuki Morizane; Shuhei Kimura; Akito Hirakata
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-11-25       Impact factor: 3.117

3.  Long-term follow-up of intravitreal bevacizumab in retinal arterial macroaneurysm: a case report.

Authors:  Shani Golan; Daphna Goldenberg; Michaella Goldstein
Journal:  Case Rep Ophthalmol       Date:  2011-12-13

4.  Foveal Exudative Macroaneurysm Treated with Intravitreal Ranibizumab.

Authors:  Carlos Menezes; Rui Carvalho; Carla Teixeira; José Alberto Lemos; Rita Gonçalves; Pedro Coelho; André Lima
Journal:  Case Rep Ophthalmol       Date:  2015-06-02

5.  Serial bevacizumab injections and laser photocoagulation for macular edema associated with a retinal artery macroaneurysm.

Authors:  Ella H Leung; Ashvini K Reddy; Anil S Vedula; Harry W Flynn
Journal:  Clin Ophthalmol       Date:  2015-04-04

6.  Retinal Arterial Macroaneurysms: Updating your Memory on RAM Management.

Authors:  Brian Evan Goldhagen; Raquel Goldhardt
Journal:  Curr Ophthalmol Rep       Date:  2019-04-16

7.  Influence of bevacizumab therapy and intraretinal hemorrhage in long-term outcomes of hemorrhagic retinal arterial macroaneurysm.

Authors:  Jae Hui Kim; Jong Woo Kim; Chul Gu Kim; Young Ju Lew; Han Joo Cho
Journal:  Sci Rep       Date:  2021-07-09       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.